BR112018076124A2 - tratamento de amd utilizando a variante de aav2 com aflibercept - Google Patents

tratamento de amd utilizando a variante de aav2 com aflibercept

Info

Publication number
BR112018076124A2
BR112018076124A2 BR112018076124A BR112018076124A BR112018076124A2 BR 112018076124 A2 BR112018076124 A2 BR 112018076124A2 BR 112018076124 A BR112018076124 A BR 112018076124A BR 112018076124 A BR112018076124 A BR 112018076124A BR 112018076124 A2 BR112018076124 A2 BR 112018076124A2
Authority
BR
Brazil
Prior art keywords
aflibercept
amd treatment
aav2 variant
amd
aav2
Prior art date
Application number
BR112018076124A
Other languages
English (en)
Portuguese (pt)
Inventor
Blumenkranz Mark
Gasmi Mehdi
Original Assignee
Adverum Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adverum Biotechnologies Inc filed Critical Adverum Biotechnologies Inc
Publication of BR112018076124A2 publication Critical patent/BR112018076124A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
BR112018076124A 2016-06-16 2017-06-16 tratamento de amd utilizando a variante de aav2 com aflibercept BR112018076124A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351234P 2016-06-16 2016-06-16
PCT/US2017/038003 WO2017218974A2 (en) 2016-06-16 2017-06-16 Treatment of amd using aav2 variant with aflibercept

Publications (1)

Publication Number Publication Date
BR112018076124A2 true BR112018076124A2 (pt) 2019-03-26

Family

ID=60663653

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018076124A BR112018076124A2 (pt) 2016-06-16 2017-06-16 tratamento de amd utilizando a variante de aav2 com aflibercept

Country Status (25)

Country Link
US (2) US20190151409A1 (https=)
EP (3) EP3471780B1 (https=)
JP (5) JP6814822B2 (https=)
KR (2) KR102218265B1 (https=)
CN (2) CN109641065A (https=)
AU (3) AU2017286673B2 (https=)
BR (1) BR112018076124A2 (https=)
CA (1) CA3027737A1 (https=)
CY (1) CY1123697T1 (https=)
DK (2) DK3471780T3 (https=)
ES (2) ES2840059T3 (https=)
FI (1) FI3795181T3 (https=)
HR (2) HRP20251248T1 (https=)
HU (1) HUE051953T2 (https=)
IL (3) IL279919B2 (https=)
LT (2) LT3471780T (https=)
MX (2) MX391779B (https=)
PL (1) PL3795181T3 (https=)
PT (2) PT3471780T (https=)
RS (2) RS67328B1 (https=)
SG (1) SG11201811232XA (https=)
SI (2) SI3471780T1 (https=)
SM (2) SMT202500400T1 (https=)
WO (1) WO2017218974A2 (https=)
ZA (1) ZA201808538B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3800191B1 (en) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
ES2840059T3 (es) * 2016-06-16 2021-07-06 Adverum Biotechnologies Inc Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
EP4653536A3 (en) 2017-03-17 2026-02-25 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
CN107661492A (zh) * 2017-08-31 2018-02-06 中山大学中山眼科中心 Vegf‑b的新用途
CN107537026A (zh) * 2017-08-31 2018-01-05 中山大学中山眼科中心 Vegf‑b的应用
AU2018350990A1 (en) * 2017-10-18 2020-05-21 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap
CN111770999A (zh) * 2017-11-27 2020-10-13 4D分子治疗有限公司 腺相关病毒变体衣壳和用于抑制血管生成的应用
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR
US20210154270A1 (en) * 2018-04-12 2021-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anti-aging compositions and methods of use
DK4364724T3 (da) 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
JP7597380B2 (ja) * 2019-03-04 2024-12-10 アドヴェラム バイオテクノロジーズ， インコーポレイテッド 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
WO2020219868A1 (en) * 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
HRP20260137T1 (hr) * 2019-09-11 2026-03-13 Adverum Biotechnologies, Inc. Liječenje očnih neovaskularnih bolesti upotrebom aav2 varijanti koje kodiraju aflibercept
CA3147843A1 (en) * 2019-09-11 2021-03-18 Mehdi Gasmi Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept
TWI819268B (zh) 2020-01-16 2023-10-21 詹姆斯 Ｗ 希爾 藉由基因轉導改變眼睛顏色
FR3111913A1 (fr) * 2020-06-30 2021-12-31 Eyevensys Construction d’adn pour le traitement de pathologies oculaires
JP7842082B2 (ja) * 2020-07-21 2026-04-07 エフティージェン コーポレーション 眼疾患を処置するための組成物および方法
CN113952474A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113952473A (zh) * 2020-07-21 2022-01-21 英斯培瑞有限公司 用于治疗眼部疾病的组合物和方法
CN113817775B (zh) * 2020-08-25 2023-02-17 南京吉迈生物技术有限公司 修饰的阿柏西普、组合物、方法及其在基因治疗中的应用
CA3192736A1 (en) * 2020-09-03 2022-03-10 University Of Massachusetts Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2021049374A (ja) * 2020-12-09 2021-04-01 株式会社三洋物産 遊技機
BR112023019056A2 (pt) * 2021-04-27 2024-01-16 Adverum Biotechnologies Inc Métodos para tratar doenças oculares usando variantes de aav2 que codificam aflibercepte
AU2023220237A1 (en) 2022-02-21 2024-08-15 Shanghai Regenelead Therapies Co., Ltd Vegf-binding molecule and pharmaceutical use thereof
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
TW202508610A (zh) 2023-08-23 2025-03-01 大陸商上海瑞宏迪醫藥有限公司 醫藥組成物及其用途
WO2025072688A2 (en) * 2023-09-27 2025-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adeno-associated virus vectors for nucleic acid delivery to retinal cells, for nucleic acid delivery across retinal regions, or for nucleic acid delivery to retinal ganglion cells and/or retinal pigment epithelium cells
WO2025073297A1 (zh) * 2023-10-06 2025-04-10 甘李药业股份有限公司 表达抗vegf融合蛋白的aav病毒载体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105755044A (zh) * 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
ES2753135T3 (es) * 2012-05-07 2020-04-07 Allergan Inc Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
TWI698240B (zh) * 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
WO2013188316A1 (en) * 2012-06-11 2013-12-19 Avalanche Biotechnologies, Inc. Optical regulation of gene expression in the retina
DK4374873T3 (da) * 2013-07-12 2025-11-03 Astellas Us Llc Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
CA2926853C (en) * 2013-10-18 2022-04-26 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
US11021519B2 (en) * 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
ES2840059T3 (es) * 2016-06-16 2021-07-06 Adverum Biotechnologies Inc Tratamiento de la DMRE mediante el uso de la variante AAV2 con aflibercept

Also Published As

Publication number Publication date
CN117531025A (zh) 2024-02-09
EP3795181A1 (en) 2021-03-24
AU2021225178A1 (en) 2021-09-30
IL314568A (en) 2024-09-01
AU2021225178B2 (en) 2025-01-30
IL263686B (en) 2021-02-28
PT3795181T (pt) 2025-11-05
DK3795181T3 (da) 2025-10-13
DK3471780T3 (da) 2020-11-23
JP2022137244A (ja) 2022-09-21
PT3471780T (pt) 2020-12-17
IL279919B2 (en) 2025-01-01
ES2840059T3 (es) 2021-07-06
IL314568B1 (en) 2025-05-01
JP2020203941A (ja) 2020-12-24
US20190151409A1 (en) 2019-05-23
HUE051953T2 (hu) 2021-04-28
EP3471780A2 (en) 2019-04-24
EP3471780A4 (en) 2019-04-24
MX2018015512A (es) 2019-04-24
CY1123697T1 (el) 2022-03-24
IL263686A (en) 2019-01-31
IL279919A (en) 2021-03-01
KR20190037228A (ko) 2019-04-05
CN109641065A (zh) 2019-04-16
FI3795181T3 (fi) 2025-10-14
SI3795181T1 (sl) 2025-11-28
KR20210021113A (ko) 2021-02-24
WO2017218974A3 (en) 2018-01-25
EP4671369A3 (en) 2026-03-18
JP2025186377A (ja) 2025-12-23
LT3471780T (lt) 2021-01-25
SMT202500400T1 (it) 2025-11-10
SMT202100010T1 (it) 2021-03-15
ES3049818T3 (en) 2025-12-18
AU2017286673B2 (en) 2021-06-24
WO2017218974A2 (en) 2017-12-21
EP4671369A2 (en) 2025-12-31
SI3471780T1 (sl) 2021-03-31
ZA201808538B (en) 2021-04-28
IL279919B1 (en) 2024-09-01
HRP20251248T1 (hr) 2026-01-16
JP6814822B2 (ja) 2021-01-20
EP3795181B1 (en) 2025-08-06
IL314568B2 (en) 2025-09-01
JP2024113193A (ja) 2024-08-21
JP2019521990A (ja) 2019-08-08
AU2025202930A1 (en) 2025-05-15
US20220265740A1 (en) 2022-08-25
MX2022004786A (es) 2022-05-16
CA3027737A1 (en) 2017-12-21
RS67328B1 (sr) 2025-11-28
MX391779B (es) 2025-03-21
RS61311B1 (sr) 2021-02-26
HRP20201842T1 (hr) 2021-04-16
SG11201811232XA (en) 2019-01-30
AU2017286673A1 (en) 2019-01-31
LT3795181T (lt) 2025-12-29
PL3795181T3 (pl) 2025-12-22
KR102218265B1 (ko) 2021-02-25
EP3471780B1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
BR112018076124A2 (pt) tratamento de amd utilizando a variante de aav2 com aflibercept
CY1125152T1 (el) Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου
AR099837A1 (es) Terapia génica para la retinitis pigmentaria
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
EP4324845A3 (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
BR112018011975A2 (pt) composições úteis no tratamento de atrofia muscular espinhal
BR112018014288A2 (pt) métodos e composições para o tratamento de doença neurológica
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
BR112019005548A2 (pt) tratamento da doença de huntington com aav
BR112016016658A2 (pt) proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
BR112016019432A8 (pt) composição terapêutica, kit e seus usos na terapia gênica contra degeneração da retina
BR112018073861A2 (pt) métodos de terapia de genes para doenças e condições relacionadas com a idade
NZ759766A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
EP4331590A3 (en) Nuclear factor erythroid 2-like 2 (nrf2) for use in treatment of age-related macular degeneration
BR112014011896A2 (pt) agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr)
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
BR112016015678B1 (pt) Polipeptídeo compreendendo um fragmento de ospa de c-terminal híbrido, seu processo de produção, seu uso, ácido nucleico, vetor, célula hospedeira, composição farmacêutica
MX2017015879A (es) Composiciones de hidroxipropil beta-ciclodextrina y metodos.
BR112018017240A2 (pt) ?polinucleotídeo, vetor de ácido nucleico, preparação farmacêutica, kit, e, método para fabricar um vetor viral adenoassociado recombinante?
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
EP4454637A3 (en) Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112018007121A2 (pt) anticorpo ou antígeno de ligação ao fragmento do mesmo, anticorpo humanizado ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o anticorpo ou um antígeno de ligação ao fragmento do mesmo, composição farmacêutica, uso do anticorpo ou um antígeno de ligação ao fragmento do mesmo e método para prevenir ou tratar infecção hbv ou uma doença associada com a infecção hbv

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25G Requested change of headquarter approved

Owner name: ADVERUM BIOTECHNOLOGIES, INC. (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]